569 related articles for article (PubMed ID: 25482928)
1. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.
Premkumar DR; Jane EP; Pollack IF
Cancer Biol Ther; 2015; 16(2):233-43. PubMed ID: 25482928
[TBL] [Abstract][Full Text] [Related]
2. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.
Jane EP; Premkumar DR; DiDomenico JD; Hu B; Cheng SY; Pollack IF
Mol Cancer Ther; 2013 Mar; 12(3):326-38. PubMed ID: 23325792
[TBL] [Abstract][Full Text] [Related]
3. Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.
Jane EP; Premkumar DR; Cavaleri JM; Sutera PA; Rajasekar T; Pollack IF
J Pharmacol Exp Ther; 2016 Feb; 356(2):354-65. PubMed ID: 26585571
[TBL] [Abstract][Full Text] [Related]
4. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
Premkumar DR; Jane EP; DiDomenico JD; Vukmer NA; Agostino NR; Pollack IF
J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of ABT-737 and SAHA induces apoptosis, mediated by Noxa upregulation, Bax activation and mitochondrial dysfunction in PTEN-intact malignant human glioma cell lines.
Foster KA; Jane EP; Premkumar DR; Morales A; Pollack IF
J Neurooncol; 2014 Dec; 120(3):459-72. PubMed ID: 25139025
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.
Jane EP; Premkumar DR; Morales A; Foster KA; Pollack IF
J Pharmacol Exp Ther; 2014 Jul; 350(1):22-35. PubMed ID: 24741074
[TBL] [Abstract][Full Text] [Related]
7. Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimetic-Induced Apoptosis.
Antonietti P; Linder B; Hehlgans S; Mildenberger IC; Burger MC; Fulda S; Steinbach JP; Gessler F; Rödel F; Mittelbronn M; Kögel D
Mol Cancer Ther; 2017 Jan; 16(1):156-168. PubMed ID: 27777286
[TBL] [Abstract][Full Text] [Related]
8. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
9. Chalepin: A Compound from
Richardson JSM; Aminudin N; Abd Malek SN
Pharmacogn Mag; 2017 Oct; 13(Suppl 3):S489-S498. PubMed ID: 29142404
[TBL] [Abstract][Full Text] [Related]
10. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.
Yacoub A; Mitchell C; Hong Y; Gopalkrishnan RV; Su ZZ; Gupta P; Sauane M; Lebedeva IV; Curiel DT; Mahasreshti PJ; Rosenfeld MR; Broaddus WC; James CD; Grant S; Fisher PB; Dent P
Cancer Biol Ther; 2004 Aug; 3(8):739-51. PubMed ID: 15197348
[TBL] [Abstract][Full Text] [Related]
11. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.
Spender LC; Inman GJ
Mol Cancer Res; 2012 Mar; 10(3):347-59. PubMed ID: 22241218
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with ABT-737 and VX-680 induces apoptosis in Bcl-2- and c-FLIP-overexpressing breast carcinoma cells.
Choi JE; Woo SM; Min KJ; Kang SH; Lee SJ; Kwon TK
Oncol Rep; 2015 Mar; 33(3):1395-401. PubMed ID: 25592064
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
[TBL] [Abstract][Full Text] [Related]
14. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W
Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinases as targets in drug-resistant neuroblastoma cells.
Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells.
Huang S; Sinicrope FA
Autophagy; 2010 Feb; 6(2):256-69. PubMed ID: 20104024
[TBL] [Abstract][Full Text] [Related]
18. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Yar Saglam AS; Alp E; Elmazoglu Z; Menevse S
Hum Exp Toxicol; 2016 May; 35(5):526-43. PubMed ID: 26183715
[TBL] [Abstract][Full Text] [Related]
19. Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells.
Klungsaeng S; Kukongviriyapan V; Prawan A; Kongpetch S; Senggunprai L
Am J Chin Med; 2020; 48(6):1475-1489. PubMed ID: 32907364
[TBL] [Abstract][Full Text] [Related]
20. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
Premkumar DR; Jane EP; Foster KA; Pollack IF
J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
